New drug may boost performance of ADHD medication
Families of children with attention-deficit/hyperactivity disorder (ADHD) may save money on their treatments by shopping at an online Canadian pharmacy.
Families of children with attention-deficit/hyperactivity disorder (ADHD) may save money on their treatments by shopping at an online Canadian pharmacy. However, not all children experience the same level of improvements from these medications. Now, a team of researchers has developed a drug that may serve as adjunct to psychostimulant regimens in children and adolescents.
ADHD is characterized by impaired focus, an inability to pay attention, poor behavior control and hyperactivity, according to the National Institute of Mental Health, a division of the National Institutes of Health. The lifetime prevalence among individuals aged 13 to 18 is 9 percent.
The scientists conducted a nine-week long randomized placebo-controlled trial in which pediatric patients taking psychostimulants for ADHD were divided into three groups: subjects taking guanfacine extended release (GXR) in the morning in addition to their regular medication, those taking GXR at night and a placebo group.
Results showed that study participants taking GXR in addition to a psychostimulant experienced greater improvements in ADHD symptoms, regardless of whether the new drug was taken in the morning or at night, as published in the Journal of the American Academy of Child and Adolescent Psychiatry. The combination of GXR and psychostimulants was just as safe as psychostimulants administered alone.
|
